Uncategorized

Novo Nordisk announced today that it plans to invest $1.2 billion (8.5 billion Danish kroner) in a new production facility in Odense, Denmark. The company said this marks the first time in this century that it breaks ground in Denmark by establishing a new production site. Novo Nordisk plans to include a state-of-the-art finished production…

Baxter recently stopped selling IV products in China as it continues its efforts to address hurricane-related supply shortages in the U.S. In a statement shared with Pharmaceutical Processing World, the Deerfield, Illinois–based company said: “After careful consideration, and given the numerous alternative IV solution suppliers that exist in the Chinese market, Baxter has suspended commercial…

MilliporeSigma, Merck KGaA’s U.S. and Canada Life Science business, announced a $76 million expansion of its ADC manufacturing capabilities and capacity. The company is expanding the capacity at its Bioconjugation Center of Excellence facility in St. Louis. This investment triples existing capacity and enhances the company’s contract development and manufacturing organization (CDMO) offering. MilliporeSigma said…

Teva Pharmaceuticals and mAbxience recently announced a strategic licensing agreement for a biosimiliar candidate that is in development for treating multiple oncology indications. The licensing agreement covers multiple global markets, including Europe and the U.S., expanding mAbxience’s global expansion strategy. The new partnership also supports Teva’s “Pivot to Growth” strategy that will expand its biosimiliar…

All companies in the pharmaceutical industry are under pressure for time, quality, compliance, and innovation. These pressures create imperatives to be both paperless and flexible to protect profitability. The stresses and imperatives apply to small-molecule pharmaceuticals, active ingredients (API), contract drug manufacturers (CDMOs), large-molecule biotechnology, and gene and cell therapy makers. Fortunately, a manufacturing execution…

Merck & Co. has announced its third quarter results, projectings its full-year 2023 revenue to be in the range of $59.7 billion to $60.2 billion. That’s roughly in line with the guidance from Pfizer, which recently adjusted its revenue forecast from $58 billion to $61 billion.  As Pfizer deals with reduced demand for COVID-19 products,…

BD announced today that it has secured ISO certification for its enterprise-level Information Security Management System. The Franklin Lakes, New Jersey–based company said the ISMS meets a rigorous set of independently audited international standards. BD says the ISO/IEC 27001:2022 certification demonstrates its commitment to protecting the company, customers and patients from cybersecurity threats. The International…

A New York federal judge has frozen the assets of several individuals and entities for their alleged role in distributing counterfeit versions of Gilead Science’s (Nasdaq:GILD) HIV medications. Presiding over the U.S. District Court for the Eastern District of New York, Judge Ann M. Donnelly also denied the defendants’ motion to dismiss the case for…

Demand for the attention-deficit/hyperactivity disorder drug Adderall (mixed amphetamine salts) has skyrocketed in the past decade. In 2021, physicians prescribed the medication and its generic equivalents 41.4 million times. Supplies of generic Adderall XR, however, remain scarce. Amneal Pharmaceuticals, Rhodes Pharmaceuticals, Par Pharmaceutical, Sandoz and Teva had the drug on backorder in late August, according…

Pfizer (NYSE:PFE) has announced a voluntary recall of five lots of Accupril (Quinapril HCl) tablets owing to elevated levels of the nitrosamine N-nitroso-quinapril.  Accupril, an angiotensin-converting enzyme (ACE) inhibitor, is indicated for treating hypertension. FDA has also approved its use as an adjunctive therapy for treating heart failure.  N-nitroso-quinapril, which can be frequently found in…